Newsroom

TORONTO--(BUSINESS WIRE)--Corpay, Inc.*, (NYSE: CPAY) un leader globale nei pagamenti aziendali, oggi ha reso noto che la sua attività Cross-Border ha stretto un accordo con Fever, una piattaforma leader globale nella scoperta e vendita di biglietti di spettacoli dal vivo specializzata in esperienze immersive, concerti a lume di candela ed eventi pop interattivi. Grazie all'accordo, Corpay diventa il partner ufficiale ed esclusivo globale di Fever per il cambio valute (FX). Grazie alla collabor...

OVERLAND PARK, Kansas--(BUSINESS WIRE)--Para empresas que implementam IA em processos de conformidade, uma data incorreta significa um prazo perdido. A falha mais perigosa é uma resposta errada que o modelo oferece com um alto grau de confiança; uma resposta que se integra silenciosamente em um cronograma de conformidade e só é descoberta depois que o prazo expirou. A Archer® divulgou hoje os resultados demonstrando que uma IA desenvolvida para fins específicos supera um modelo de linguagem ext...

BUTTE, Mont. & SIOUX FALLS, S.D.--(BUSINESS WIRE)--NorthWestern Energy Group, Inc. d/b/a NorthWestern Energy (Nasdaq: NWE) today announced that it will host an investor webinar on Thursday, July 30, 2026, at 3:30 p.m. Eastern to review its financial results for the quarter ending June 30, 2026. The Company also plans to issue a news release detailing its financial results the evening of Wednesday, July 29, 2026. To register for the webinar, please visit https://northwesternenergy.com/earnings-r...

TORONTO--(BUSINESS WIRE)--Corpay, Inc.* (NYSE : CPAY), leader mondial des paiements d’entreprise, a annoncé aujourd’hui que sa division Cross-Border a conclu un accord avec Fever, une plateforme mondiale de premier plan dédiée à la découverte de spectacles live et à la billetterie. Cette plateforme est spécialisée dans les expériences immersives, les concerts aux chandelles et les événements interactifs éphémères. Conformément à cet accord, Corpay devient le partenaire officiel exclusif de Feve...

PHOENIX--(BUSINESS WIRE)--VIVAZEN®, the nation’s leading botanical wellness company, welcomes the Drug Enforcement Administration’s (DEA) decision to classify 7-hydroxymitragynine (7-OH) and three related drugs as Schedule I drug. 7-OH is a dangerous synthetic, lab-made drug that HHS and FDA have described as harmful and addictive. 7-OH has raised serious concerns for public health and consumer safety. This move critically distinguishes these harmful synthetic drugs and the natural botanical kr...

LOS ANGELES--(BUSINESS WIRE)--Kilroy Realty Corporation (NYSE: KRC) ("Kilroy" or the “Company”) announced today it will release second quarter 2026 financial results after the market closes on Monday, July 27, 2026. Kilroy will hold a conference call to discuss the results at 10:00 a.m. PT / 1:00 p.m. ET on Tuesday, July 28, 2026. To participate and obtain conference call dial-in details, register by using the following link: https://events.q4inc.com/analyst/213776497?pwd=miK0Lhqd. This call wi...

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, Jumana Capital Investments LLC and Christopher R. Martin (collectively, the “Radoff-Jumana Group” or “we”), who collectively own approximately 9.1% of the outstanding shares of Genesco Inc. (NYSE: GCO) (“Genesco” or the “Company”), today issued the following statement: “The Company’s proxy statement touts Joanna Barsh’s supposed credentials to serve on Genesco’s Board of Directors. It claims, inaccurately, that she has ‘Public Company Leadership (CEO...

NEW YORK--(BUSINESS WIRE)--American International Group, Inc. (NYSE: AIG) will report financial results for the second quarter ended June 30, 2026, after the market closes on Thursday, August 6, 2026. AIG’s press release and financial supplement will be available in the Investors section of AIG’s website at https://www.aig.com. AIG will also host a conference call on Friday, August 7, 2026, at 8:30 a.m. ET to review these results. The live, listen-only webcast is open to the public and can be a...

北卡羅來納州羅利市與倫敦--(BUSINESS WIRE)--(美國商業資訊)-- Caidya今日宣布與Simbec-Orion達成策略性整合，旨在彌合早期科學洞察與全球臨床執行之間的落差。Caidya與Simbec-Orion的整合打造出具差異化的專業臨床研究機構(CRO)平台，使各項計畫得以擴展規模，同時維持專注度、速度與責任機制。 此次策略性整合匯集互補優勢，為創新生物製藥公司打造更完整的研發合作夥伴。憑藉在歐洲、美洲、亞太及中國已建立的營運據點，整合後的組織能在最關鍵的區域提供具實質意義的專業能力與執行能力。 Simbec-Orion具備早期臨床藥理能力，並在後期複雜的腫瘤與罕見疾病試驗方面擁有深厚的治療領域專業，協助申辦方在研發生命週期早期做出關鍵決策。雙方合併後，將強化支援複雜跨境專案的能力，並提供更完整的銜接路徑，從人體第一次試驗，涵蓋健康受試者與病患族群，一直到產品註冊階段。 其結果是更廣泛的能力、更深入的專業，以及更高的連續性，並以客戶對專業型臨床研究機構所期待的即時回應、責任機制與緊密協作方式交付。 憑藉在歐洲長期建立的營運基礎，以及近五十年支持創新生物製藥公司的...

北卡罗来纳州罗利市与伦敦--(BUSINESS WIRE)--(美国商业资讯)-- Caidya今日宣布与Simbec-Orion达成战略合并，旨在打破早期科学洞察与全球临床执行之间的壁垒。Caidya与Simbec-Orion的强强联合，打造了一个极具优势的专科临床CRO（合同研究组织）平台，在保持专注、速度与问责的同时，助力各研发项目实现规模化扩展。 此次战略合并汇聚了双方的互补优势，旨在为创新型生物医药企业打造一个更具全方位能力的研发合作伙伴。合并后的机构在欧洲、美洲、亚太及中国地区拥有成熟的业务网络，能够在这些最核心的区域提供深厚的专业知识与卓越的执行能力。 Simbec-Orion拥有早期临床药理学能力，以及在后期复杂的肿瘤学和罕见病试验领域的深厚治疗专长，旨在助力申办方在研发生命周期的早期阶段做出关键决策。两家机构强强联合，不仅强化了其支持复杂跨国项目的能力，更能够提供一条从首次人体（FIH）研究（涵盖健康志愿者和患者）到上市注册申报的、更具连贯性的端到端研发路径。 此次合并将赋予我们更广泛的业务能力、更深厚的专业造诣以及更具连贯性的全流程服务，同时，我们将一如既往地保持专...